EA201991716A1 - АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ГЕНТИНГТОНА - Google Patents
АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ГЕНТИНГТОНАInfo
- Publication number
- EA201991716A1 EA201991716A1 EA201991716A EA201991716A EA201991716A1 EA 201991716 A1 EA201991716 A1 EA 201991716A1 EA 201991716 A EA201991716 A EA 201991716A EA 201991716 A EA201991716 A EA 201991716A EA 201991716 A1 EA201991716 A1 EA 201991716A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- gentington
- treatment
- pparγ agonist
- pparγ
- Prior art date
Links
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201991716A1 true EA201991716A1 (ru) | 2020-02-04 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991716A EA201991716A1 (ru) | 2017-01-18 | 2018-01-18 | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ГЕНТИНГТОНА |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (enExample) |
| EP (1) | EP3570841A4 (enExample) |
| JP (1) | JP2020505448A (enExample) |
| KR (1) | KR20190122664A (enExample) |
| CN (1) | CN110461330A (enExample) |
| AU (1) | AU2018210165A1 (enExample) |
| BR (1) | BR112019014529A2 (enExample) |
| CA (1) | CA3050104A1 (enExample) |
| EA (1) | EA201991716A1 (enExample) |
| IL (1) | IL268008A (enExample) |
| MX (1) | MX2019008535A (enExample) |
| SG (1) | SG11201906644YA (enExample) |
| WO (1) | WO2018136635A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| JP2008515978A (ja) * | 2004-10-13 | 2008-05-15 | ユニバーシティ オブ コネチカット | カンナビネルジック脂質リガンド |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| EP2448412B1 (en) * | 2009-07-01 | 2019-05-01 | JDS Therapeutics, LLC | Chromium complexes as enhancers of brain glucose transporters |
| AU2014364447A1 (en) * | 2013-12-20 | 2016-08-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay Huntington's disease progression |
-
2018
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018136635A1 (en) | 2018-07-26 |
| SG11201906644YA (en) | 2019-08-27 |
| AU2018210165A1 (en) | 2019-08-01 |
| KR20190122664A (ko) | 2019-10-30 |
| JP2020505448A (ja) | 2020-02-20 |
| EP3570841A1 (en) | 2019-11-27 |
| CA3050104A1 (en) | 2018-07-26 |
| IL268008A (en) | 2019-09-26 |
| US20190350918A1 (en) | 2019-11-21 |
| BR112019014529A2 (pt) | 2020-02-27 |
| CN110461330A (zh) | 2019-11-15 |
| MX2019008535A (es) | 2019-12-02 |
| EP3570841A4 (en) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| EA201791002A1 (ru) | Новые соединения, модулирующие fxr (nr1h4) | |
| EA201591743A1 (ru) | СТИМУЛЯТОРЫ sGC | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
| AR096478A1 (es) | Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos | |
| EA201792096A3 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| EA201891440A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| BR112017000520A2 (pt) | composto ou sal do mesmo, uso um composto ou de um sal, e, kit. | |
| EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
| EA201792287A1 (ru) | Способы лечения рака | |
| EA201892287A1 (ru) | Фармацевтические комбинации для лечения рака | |
| CL2017002960A1 (es) | Compuesto para la profilaxis o el tratamiento de daño al órgano | |
| EA201990512A1 (ru) | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ | |
| EA201992364A1 (ru) | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА | |
| MX2019011867A (es) | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. | |
| EA201991716A1 (ru) | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ГЕНТИНГТОНА |